Gavi Alliance Strategy 2016-2020: Goal level indicators and disease dashboard

BOARD MEETING
Peter Hansen and Hope Johnson
10-11 June 2015, Geneva
# Gavi, The Vaccine Alliance Strategy 2016-2020

## Mission

To save children’s lives and protect people’s health by increasing equitable use of vaccines in lower income countries

## Principles

- **Country-led**: Respond to and align with country demand, supporting national priorities, budget processes and decision-making
- **Community-owned**: Ensure engagement of communities to increase accountability and sustain demand and impact
- **Globally engaged**: Contribute to the Global Vaccine Action plan, align with the post-2015 global development priorities and implement the aid effectiveness principles
- **Catalytic & sustainable**: Provide support to generate long term sustainable results including country self-financing of vaccines through the graduation process

## Goals

### Accelerate equitable uptake and coverage of vaccines

- **Aspiration 2020**
  - < 5 mortality rate
  - Future deaths averted
  - Future DALYs averted
  - # of children vaccinated with GAVI support
  - Vaccines sustained after transition

### Increase effectiveness and efficiency of immunisation delivery as an integrated part of strengthened health systems

- **Objectives**
  - Increase coverage and equity of immunisation
  - Support countries to introduce and scale up new vaccines
  - Respond flexibly to the special needs of children in fragile countries

### Improve sustainability of national immunisation programmes

- **Objectives**
  - Enhance national and sub-national political commitment to immunisation
  - Ensure appropriate allocation and management of national human and financial resources to immunisation through legislative and budgetary means
  - Prepare countries to sustain performance in immunisation after graduation

### Shape markets for vaccines and other immunisation products

- **Objectives**
  - Ensure adequate and secure supply of quality vaccines
  - Reduce prices of vaccines and other immunisation products to an appropriate and sustainable level
  - Incentivise development of suitable and quality vaccines and other immunisation products

## GeO-Level Indicators

- **Reach of routine coverage**: penta3 and measles first dose
- **Breadth of protection**: average coverage across all supported vaccines
- **Equity of coverage and barriers**
  - Distribution by: geography
  - wealth quintiles
  - education status of mothers/female caretakers
  - fragile state status
- **Supply chain DRAFT**: rolling average Effective Vaccine Management scores
- **Data quality DRAFT**: difference between administrative coverage and survey
- **Access, demand & service delivery DRAFT**: penta1 coverage and drop out
- **Integration DRAFT**: increased oral rehydration coverage following rotavirus vaccine introductions
- **Civil society & private sector DRAFT**: % of countries with civil society or private sector partners in national plans
- **Co-financing**: % countries fulfilling co-financing commitments
- **Country investments in routine immunisation**: % countries with increasing investment in routine immunisation per child
- **Programmatic sustainability**: % countries on track for successful graduation
- **Strengthen institutional capacity for national decision-making, management & monitoring**: TBD

## Strategic Enablers

- **A) Country leadership management & coordination**
  - (1) Strengthen institutional capacity for national decision-making, programme management and monitoring
  - (2) Support availability and use of quality data for country-level decision making
- **B) Resource mobilisation**
  - (1) Secure long-term predictable funding for GAVI Alliance programmes as a prerequisite for continued success
  - (2) Harness the capacity of the private sector, including through innovative finance mechanisms and contributions from vaccine
- **C) Advocacy**
  - (1) Strengthen national political and subnational commitment for immunisation
  - (2) Strengthen global political commitment for immunisation, health and development
- **D) Monitoring & Evaluation**
  - Support GAVI as a learning Alliance through (i) Effective routine programme monitoring and management and (ii) Regular evaluation of the relevance, effectiveness, impact, and efficiency of the GAVI Alliance’s investments to inform evidence-based policy development

## Disease dashboard

**Empirical measures of health outcomes**
- Hepatitis B
- Rotavirus diarrhea
- Measles

**Integrated**: Foster integration of immunisation with other health interventions, harmonising support by the GAVI Alliance with other partners’
- **Innovative**: Foster and take to scale innovation in development models, financing instruments, public health approaches, immunisation-related technologies and delivery science
- **Collaborative**: As a public private partnership, convene immunisation stakeholders and leverage the strengths of all Alliance partners through shared responsibility at both global and national level
- **Accountable**: Maximise Alliance cooperation and performance through transparent accountability mechanisms

**Aspiration 2020**
- <5 mortality rate
- Future deaths averted
- Future DALYs averted
- # of children vaccinated with GAVI support
- Vaccines sustained after transition

**Disease dashboard**
- Empirical measures of health outcomes:
  - Hepatitis B
  - Rotavirus diarrhea
  - Measles
## Aspiration 2020 Indicators

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;5 mortality rate</td>
<td>TBD</td>
</tr>
<tr>
<td>Future deaths averted</td>
<td>5 – 6 Million</td>
</tr>
<tr>
<td>Future DALYs averted</td>
<td>&gt; 250 Million</td>
</tr>
<tr>
<td>Number of children vaccinated with Gavi support</td>
<td>&gt; 300 Million</td>
</tr>
<tr>
<td>New indicator recommended: % of countries sustaining delivery of all recommended vaccines in their routine programmes after transition</td>
<td>100%</td>
</tr>
</tbody>
</table>
# Disease Dashboard

## Recommended Indicators

<table>
<thead>
<tr>
<th>Disease</th>
<th>Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Hepatitis B</strong></td>
<td>- Number of countries that have &lt;2% hepatitis B surface antigen (HBsAg) prevalence among children &lt;5 years of age</td>
</tr>
<tr>
<td><strong>Diarrhoea</strong></td>
<td>- Median % (and interquartile range) of acute gastroenteritis hospitalisations positive for rotavirus among children less than one year of age among countries with any surveillance site meeting inclusion criteria</td>
</tr>
<tr>
<td><strong>Measles</strong></td>
<td>- Number of countries reporting an annual incidence of less than 5 measles cases per million population.</td>
</tr>
</tbody>
</table>
### Six indicators recommended in three areas

| Reach of routine coverage          | 1. Coverage with 3rd dose of pentavalent vaccine  
                                      | 2. Coverage with first dose of measles vaccine  |
|-----------------------------------|------------------------------------------------|
| Breadth of protection             | 3. Average coverage across all Gavi supported vaccines delivered through routine systems |
| Equity of coverage and barriers to immunisation | 4. Geographic distribution  
                                      | • % of countries with all districts having ≥80% penta3 vaccination coverage  
                                      | 5. Wealth quintile distribution  
                                      | • % of countries in which penta3 coverage in poorest quintile is within 10 percentage points of penta3 coverage in wealthiest quintile  
                                      | 6. Distribution by education status of mother/female caretakers  
                                      | • % of countries in which penta3 coverage among children whose mothers/caretakers received no education is within 20 percentage points of coverage among children whose mothers/caretakers have received secondary education or higher |
Indicators under development:
To be presented to PPC in October and Board in December
<table>
<thead>
<tr>
<th>Indicator</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Co-financing</strong></td>
<td>• % of countries fulfilling co-financing commitments</td>
</tr>
<tr>
<td><strong>Country investments in routine immunisation</strong></td>
<td>• % of countries with increasing investment in routine immunisation per child relative to 2015 baseline (with average amount invested and average % of increase over baseline tracked)</td>
</tr>
<tr>
<td><strong>Programmatic sustainability</strong></td>
<td>• % of countries on track for successful graduation</td>
</tr>
<tr>
<td></td>
<td>• Supplement with fourth indicator of strengthening institutional capacity for national decision making, programme management and monitoring</td>
</tr>
</tbody>
</table>
### SG4

#### Recommended Indicators

<table>
<thead>
<tr>
<th>Category</th>
<th>Indicators</th>
</tr>
</thead>
</table>
| **Adequate and uninterrupted supply** | • % of vaccine markets for which supply meets Gavi demand  
  • Supplement with fourth indicator of healthy market dynamics |
| **Reduction in price**          | • Reduction in weighted average price of fully vaccinating a child with pentavalent, pneumococcal and rotavirus vaccines |
| **Innovation**                  | • # of vaccines and immunisation products with improved characteristics procured by Gavi that deliver country-level impact |
Following review at its May meeting, the PPC recommended to the Gavi Board that it:

A. **Approve** the indicators for the Gavi Strategy 2016-2020 recommended in Section B of Document 13 for inclusion in ‘Aspiration 2020’, the disease dashboard, including Option 2 as a measles indicator, and under each strategic goal **other than** indicators for strategic goal 2;

B. **Request** the Secretariat to present indicators for strategic goal 2, an additional indicator of healthy market dynamics and an additional indicator of institutional capacity for national decision-making, programme management and monitoring to the PPC in October 2015 for recommendation to the Board in December 2015;

C. **Request** the Secretariat to present targets for the indicators for each strategic goal to the PPC in October 2015 for recommendation to the Board in December 2015;
Following review at its May meeting, the PPC recommended to the Gavi Board that it:

D. **Request** the Secretariat to work with partners in advance of the October PPC to finalise details related to the definitions and measurement approaches for all indicators across the disease dashboard and strategic goals, and provide an updated indicator definition document for the PPC’s information in October 2015.
THANK YOU